NASDAQ$ABOS
Acumen Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Acumen Pharmaceuticals reported financial results for the third quarter of 2022 and provided a business update.
Acumen Pharmaceuticals reported a net loss of $10.7 million for the third quarter of 2022, compared to a net loss of $3.9 million for the same period in 2021. As of September 30, 2022, cash, cash equivalents and marketable securities totaled $200.2 million.
- INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease continues to progress.
- Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023.
- ACU193 was granted Fast Track designation from the U.S. FDA for the treatment of early Alzheimer’s disease.
- Cash, cash equivalents and marketable securities of $200.2 million as of Sept. 30, 2022 expected to be sufficient to support clinical and operational goals through 2025.
Headline financials
Revenue & EPS history
Acumen · Revenue · Quarterly
$12K
Forward guidance
Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from the INTERCEPT-AD trial in the second half of 2023.
Tailwinds
- INTERCEPT-AD enrollment remains ongoing.
- Patient screening and enrollment is continuing for INTERCEPT-AD, with 17 active clinical trial sites currently recruiting patients.
- The study has progressed as planned in the protocol and blinded safety data for ACU193 are consistent with our expectations.
- Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023.
- Fast Track designation is granted to drugs being developed for the treatment of serious or life-threatening conditions where there is an unmet medical need.
Headwinds
- Forward-looking statements are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics.
- Such risks may be amplified by the impacts of the COVID-19 pandemic, geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets.
- Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.
- Decrease in cash related to funding ongoing operations.
- Increased costs related to personnel, accounting, marketing, recruiting and travel expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2022
+0.6%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-6.1%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+35.9%
Q1 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | -11.7% | — | |
| Q4 2025 | -2.3% | -10.3% | -2.3% | |
| Q3 2025 | -1.5% | -19.8% | +8.6% | |
| Q1 2025 | +0.0% | +1.9% | +8.6% | |
| Q4 2024 | +6.0% | -7.3% | -6.9% | |
| Q3 2024 | -21.4% | -25.5% | -35.7% | |
| Q2 2024 | -1.6% | +0.4% | -4.3% | |
| Q1 2024 | +13.1% | +8.6% | -21.4% | |
| Q4 2023 | -3.5% | +8.0% | -20.6% | |
| Q3 2023 | +12.1% | +20.0% | +53.2% | |
| Q2 2023 | -3.1% | +2.0% | -19.9% | |
| Q1 2023 | +35.9% | +15.5% | +0.4% | |
| Q4 2022 | +2.3% | +3.6% | -4.1% | |
| Q3 2022 | -5.1% | -10.6% | -15.3% | |
| Q2 2022 | +4.6% | -11.5% | +9.4% | |
| Q1 2022 | +9.6% | +4.5% | +7.8% | |
| Q4 2021 | -14.8% | -22.0% | -22.2% | |
| Q3 2021 | -17.1% | -23.9% | -46.7% | |
| Q2 2021 | +1.6% | +13.9% | +1.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro